Cargando…
Immune checkpoint inhibitors in penile cancer
Autores principales: | Buonerba, Carlo, Scafuri, Luca, Costabile, Ferdinando, D’Ambrosio, Bruno, Gatani, Simona, Verolino, Pasquale, Trolio, Rossella Di, Cosimato, Vincenzo, Verde, Antonio, Lorenzo, Giuseppe Di |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Science Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256326/ https://www.ncbi.nlm.nih.gov/pubmed/34258024 http://dx.doi.org/10.2144/fsoa-2021-0044 |
Ejemplares similares
-
Mediterranean Diet as a Supportive Intervention in Cancer Patients: Current Evidence and Future Directions
por: Rubino, Roberta, et al.
Publicado: (2022) -
Effective Management of Nasal Vestibule Squamous Cell Carcinoma with Cemiplimab: A Case Report
por: Costabile, Ferdinando, et al.
Publicado: (2023) -
Fisetin as an adjuvant treatment in prostate cancer patients receiving androgen-deprivation therapy
por: Lorenzo, Giuseppe Di, et al.
Publicado: (2022) -
Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study
por: Di Lorenzo, Giuseppe, et al.
Publicado: (2013) -
Kaempferol, Myricetin and Fisetin in Prostate and Bladder Cancer: A Systematic Review of the Literature
por: Crocetto, Felice, et al.
Publicado: (2021)